


DIGEP-PRED 2.0: A WEB-SERVICE FOR PREDICTING DRUG-INDUCED CELL SIGNALING AND GENE EXPRESSION CHANGES


S.M. Ivanov, A.V. Rudik, A.A. Lagunin, D.A. Filimonov, V.V. Poroikov

Main applications of drug-induced gene expression data

Connectivity Map



Pathway analysis



DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on structural formula

Alexey Lagunin, Sergey Ivanov, Anastasia Rudik, Dmitry Filimonov, Vladimir Poroikov

Bioinformatics. 2013; 29(16): 2062-3.

SMILES

Pa>0.5 ▼

Save *.csv Save *.sdf

mRNA based prediction result

Pa	Pi	DownRegulation
0.825	0.026	<u>ITGAV</u>
0.767	0.035	<u>NSF</u>
0.651	0.027	<u>APOA1</u>
0.626	0.092	<u>MYBL1</u>
0.653	0.123	<u>ALDH18A1</u>
0.515	0.180	<u>TOB1</u>

Pa	Pi	UpRegulation
0.690	0.033	<u>TMEM41B</u>
0.624	0.074	<u>FAM49A</u>
0.576	0.083	<u>C10ORF118</u>
0.557	0.087	<u>WIPI1</u>
0.555	0.112	<u>PLXNA2</u>
0.515	0.142	<u>PCDH17</u>

Protein based prediction result

Pa	Pi	DownRegulation
0.686	0.006	<u>AGT</u>

Pa	Pi	UpRegulation
0.603	0.018	<u>REN</u>
0.567	0.066	<u>CAT</u>

View Help

Chemical structure: HS-CH₂-CH(CH₃)-C(=O)-N(Cyclopentyl)-C(=O)-OH

Make prediction




<https://ctdbase.org/>




<http://www.way2drug.com/PASSOnline>

DIGEP-Pred 2.0 web application: main ideas



Prediction of drug-induced gene expression changes



ConnectivityMap

MCF7
HL60
PC3

X

$ \log FC $
0.5
0.7
1
1.5
2

15 training sets



Comparative Toxicogenomics Database

mRNA level

Protein level

2 training sets



[http://www.way2drug.com/
PASSOnline](http://www.way2drug.com/PASSOnline)

MNA descriptors

Modified naïve Bayes approach



Average accuracy = 87.5 %

Examples of biological activity:

“ADGRB3 UpRegulation”, “BCL2 DownRegulation”

Prediction of drug-induced gene expression changes

Dataset	logFC	N of compounds	Selected activities	N of unique genes	Average accuracy, %
cMAP MCF7	0.5	856	3414	3027	84.6
	0.7		2404	2179	86.0
	1		1378	1283	86.9
	1.5		495	482	88.1
	2		218	216	88.9
cMAP PC3	0.5	830	2408	2227	83.9
	0.7		1842	1709	85.2
	1		1063	1008	85.9
	1.5		442	433	85.8
	2		200	196	86.2
cMAP HL60	0.5	538	3589	3334	85.6
	0.7		2722	2568	87.1
	1		1564	1508	89.4
	1.5		526	522	91.2
	2		200	200	91.1
CTD mRNA	-	2620	18425	13377	86.5
CTD protein	-	2671	3695	2932	94.8

Pathway enrichment analysis

Signaling and metabolic pathways	KEGG pathways (https://www.genome.jp/kegg/pathway.html) Reactome pathways (https://reactome.org/)
Cellular processes	Gene Ontology biological processes (https://geneontology.org/)
Diseases	DisGeNET (https://www.disgenet.org/)
Transcription factors	CollecTRI (https://github.com/saezlab/CollecTRI) (Müller-Dott S. et al. Nucleic Acids Res. 2023;51(20):10934-10949)

Prediction of protein targets (molecular mechanisms of action)



PubChem



Ki, IC₅₀ < 10 μM

Percent of inhibition > 50%



656011 compounds for training



[http://www.way2drug.com/
PASSOnline](http://www.way2drug.com/PASSOnline)



1940 individual proteins

2170 molecular mechanisms of action

Examples:


Adenosine receptor A2a agonist,
Amphiregulin inhibitor

Average accuracy = 98 %

“Upstream” analysis

- ✓ Transcription factors (TFs) from enrichment analysis results
- ✓ Signaling network from OmniPath database (<https://omnipathdb.org/>)
(Türei D. et al. Nat Methods. 2016;13(12): 966-967)

Shortest path lengths d



$$Score = \sum_{i=1}^n \frac{1}{1 + d_i}$$


Yu H. et al. BMC Syst Biol. 2016;10 Suppl 1(Suppl 1):2.
Lee T., Yoon Y. BMC Bioinformatics. 2018; 19(1): 446.

DIGEP-Pred 2.0 free available web application

<https://www.way2drug.com/digep-pred/>




User's
structural
formula



Structure-activity
relationships

Predicted
direct
targets




Predicted
gene
expression
changes

Predicted gene expression changes for tofacitinib

Home
Training Set
Products/Services
Interpretation
Contacts

PDF
Copy
CSV
Excel
+ Enrichment analysis
+ Potential target search
Show 10 entries



The image shows the chemical structure of tofacitinib (Ruxolitinib), which is a piperazine derivative. It features a central piperazine ring substituted with a 2-(4-methylphenyl)ethyl group at one position and a 2-(5-methyl-2-oxo-2H-imidazol-1-yl)ethyl group at the other. The imidazole ring has a methyl group at the 5-position.

Powered by ChemAxon

Pa	Pi	Genes	IAP, LOO CV
0.995	0.000	CXCL11	0.755
0.980	0.001	IFI35	0.773
0.961	0.001	USP18	0.751
0.949	0.000	IRF7	0.819
0.920	0.001	RSAD2	0.785
0.910	0.002	IFIT3	0.779
0.909	0.001	IFIT2	0.803

Showing 1 to 10 of 59 entries

Previous 1 2 3 4 5 6 Next

Dataset: CTD_mRNA

Cut-off: Pa > 0.3

Regulation: Down regulation

Choose model to perform prediction

Choose probability threshold

Choose direction of gene expression changes

Make prediction **Input** **Clear**

Disease enrichment results

Disgenet diseases

Gene Ontology processes

KEGG pathways

Reactome pathways

Copy

CSV

Excel

Show 10 entries

Search:

Name	ID disease	n	N	odds_ratio	-lg10(p.value)	-lg10(adj.p)
Myocardial Ischemia	C0151744	8	218	16.625	7	5
Celiac Disease	C0007570	5	48	44.838	7	5
Arthritis, Adjuvant-Induced	C0003865	4	43	39.345	5	4
Arthritis, Collagen-Induced	C0971858	4	43	39.345	5	4
Arthritis, Experimental	C0993582	4	43	39.345	5	4
Rheumatoid Arthritis	C0003873	6	190	13.789	5	4

Potential anti-COVID-19 mechanisms of tofacitinib

[Disgenet diseases](#)[Gene Ontology processes](#)[KEGG pathways](#)[Reactome pathways](#)[Copy](#)[CSV](#)[Excel](#)

Show 10 entries

Search:

Name	ID pathway	n	N	odds_ratio	-lg10(p.value)	-lg10(adj.p)
Coronavirus disease - COVID-19	hsa05171	8	232	15.614	7	6

Category: 6. Human Diseases**Subcategory:** 6.3 Infectious disease: viral**Gene:** CCL2; CXCL10; IL6; MMP1; MMP3; MX1; OAS1; STAT1**p.value:** 1.54e-7**adj.p:** 3.06e-6

Transcription factor enrichment results

Potential targets

Transcription factors

Copy

CSV

Excel

Show 10 entries

Search:

Transcription factor	n	N	odds_ratio	-lg10(p.value)	-lg10(adj.p)
STAT1	14	303	23.646	13	11
IRF9	7	27	115.664	12	10
IRF1	10	168	28.126	11	9
IRF2	7	61	51.240	9	8

Genes CXCL10; CXCL11; IFI27; IFI35; IL6; TNFSF10; USP18

p.value: 3.86e-10

adj.p: 1.14e-8

Tofacitinib protein targets – master regulators

Potential targets

Transcription factors

Copy

CSV

Excel

Show 10 entries

Search:

Mechanism of action	Pa	Pi	Gene symbol	Uniprot ID	ChEMBL family level 1	ChEMBL family level 2	Network score	Rank
 Tyrosine-protein kinase JAK2 inhibitor	0.606	0.003	JAK2	O60674	Enzyme	Kinase	25.0	1
 Tyrosine-protein kinase Lck inhibitor	0.286	0.009	LCK	P06239	Enzyme	Kinase	27.1	2
 Mitogen-activated protein kinase kinase kinase 1 inhibitor	0.393	0.045	MAP4K1	Q92918	Enzyme	Kinase	25.8	3

Conclusions

A new version of the DIGEP-Pred 2.0 web application has been created. It can be used for:

- 1** Prediction of gene expression changes induced by drug-like compounds in various conditions
- 2** Estimation of pathways, cellular processes, transcription factors and diseases associated with studied compound
- 3** Identification of the most probable protein targets of compound which are potentially responsible for induced gene expression changes

To obtain all this information, the user has to provide only the structural formula of a compound

DIGEP-Pred 2.0: A web application for predicting drug-induced cell signaling and gene expression changes

Sergey M. Ivanov^{1,2}  | Anastasia V. Rudik¹ | Alexey A. Lagunin^{1,2} |
Dmitry A. Filimonov¹ | Vladimir V. Poroikov¹

¹Department of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia

²Department of Bioinformatics, Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence

Sergey M. Ivanov, Department of Bioinformatics, Institute of Biomedical Chemistry, Pogodinskaya Street, 10 bldg. 8, Moscow 119121, Russia.
Email: smivanov7@gmail.com

Funding information

Program for Basic Research in the Russian Federation, Grant/Award Number: No. 122030100170-5

Abstract

The analysis of drug-induced gene expression profiles (DIGEP) is widely used to estimate the potential therapeutic and adverse drug effects as well as the molecular mechanisms of drug action. However, the corresponding experimental data is absent for many existing drugs and drug-like compounds. To solve this problem, we created the DIGEP-Pred 2.0 web application, which allows predicting DIGEP and potential drug targets by structural formula of drug-like compounds. It is based on the combined use of structure-activity relationships (SARs) and network analysis. SAR models were created using PASS (Prediction of Activity Spectra for Substances) technology for data from the Comparative Toxicogenomics Database (CTD), the Connectivity Map (CMap) for the prediction of DIGEP, and PubChem and ChEMBL for the prediction of molecular mechanisms of action (MoA). Using only the structural formula of a compound, the user can obtain information on potential gene

Acknowledgement

Anastasia Rudik, Ph.D

Alexey Lagunin, Dr.Sci., Prof.

Dmitry Filimonov, Ph.D

Vladimir Poroikov, Dr.Sci., Prof.,
Corresponding Member of RAS



This work has been supported within the framework of the Program for Basic Research in the Russian Federation for a long-term period (2021–2030) (No. 122030100170-5).

If you have any questions, please feel free to contact us:

Sergey Ivanov, Ph. D.

Laboratory for Structure-Function Based Drug Design

Institute of Biomedical Chemistry, Moscow, Russia

Tel: (7-499) 246-09-20

E-mail: smivanov7@gmail.com

Thank you for your attention!

